The combined use of PI3K inhibitors and MEK inhibitors can significantly inhibit the growth of bladder cancer cells, overcome the resistance of single agents, and exhibit stronger anti-tumor activity than single drugs (52, 53) (Figure 1). Here, MAP2K7 is linked to urinary bladder carcinoma.